Drug intelligence / Profile preview

hexapeptide-11

Development stage
Unknown
Lead developer
Lonza
Modality
Peptides
Administration
Topical
01

Overview

Hexapeptide-11 is a synthetic bioactive peptide with the amino acid sequence Phe-Val-Ala-Pro-Phe-Pro (FVAPFP), originally isolated from yeast extracts. It is primarily utilized in cosmeceutical applications for its anti-aging and skin-rejuvenating properties. The peptide acts as a modulator of the proteostasis network, activating the Nrf2-mediated antioxidant response, the proteasome, and autophagy pathways to protect fibroblasts from oxidative stress and premature senescence. Additionally, it enhances skin firmness and elasticity by stimulating collagen synthesis and upregulating hyaluronic acid production through the induction of HAS2 and EGR3 expression, while simultaneously downregulating the hyaluronidase HYAL2. Although widely incorporated into topical skincare formulations to reduce fine lines and wrinkles, it is not currently developed as a pharmaceutical agent for the treatment of medical diseases.

Brand names
Peptamide-6Peptamide6Peptamide 6
Other names
FVAPFPPhe-Val-Ala-Pro-Phe-Pro
02

Targets

26S proteasomeEGR3 (Early growth response protein 3)HAS1 (Hyaluronan synthase 2)HYAL2 (Hyaluronidase-2)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)

Beyond the preview

Go deeper on hexapeptide-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hexapeptide-11.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call